Search results for "urologic and male genital diseases"

showing 10 items of 459 documents

Low frequency of HLA haplotype loss associated with loss of heterozygocity in chromosome region 6p21 in clear renal cell carcinomas.

2004

HLA class I loss or downregulation is a widespread mechanism used by tumor cells to avoid tumor recognition by cytotoxic T lymphocytes favoring tumor immune escape. Multiple molecular mechanisms are responsible for these altered HLA class I tumor phenotypes. It has been described in different epithelial tumors that loss of heterozygosity (LOH) at chromosome region 6p21.3 is a frequent mechanism that leads to HLA haplotype loss, ranging between 40 and 50%, depending on the tumor entity analyzed. Here we have tested the frequency of LOH at 6p21 chromosome region in Renal Cell Carcinomas (RCC) of the clear cell and chromophobe subtype. A low frequency of HLA haplotype loss (6.6%) was found in …

Cancer ResearchPathologymedicine.medical_specialtyLoss of HeterozygosityChromophobe cellHuman leukocyte antigenBiologyurologic and male genital diseasesLoss of heterozygosityAntigens NeoplasmHLA AntigensmedicineCytotoxic T cellHumansneoplasmsCarcinoma Renal CellHaplotypeCytogeneticsKidney NeoplasmsGene Expression Regulation NeoplasticOncologyHaplotypesClear cell carcinomaChromosomes Human Pair 6Clear cellAdenocarcinoma Clear CellMicrosatellite RepeatsInternational journal of cancer
researchProduct

Immunogenic properties of renal cell carcinoma and the pathogenesis of osteolytic bone metastases.

2009

The immunogenic properties of renal cell carcinoma (RCC) on bone osteolysis were investigated. mRNA expression of three proinflammatory cytokines, monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6) and interleukin-8 (IL-8), were determined in a panel of RCC lines (CRBM 1990, ACHN and Caki-1). Moreover proinflammatory cytokine mRNA expression and protein levels of adhesion molecules, intercellular adhesion molecule-1 (ICAM-1) and E-selectin, on human umbilical vein endothelial cells (HUVEC) incubated with the conditioned media from RCC lines were evaluated. RCC express mRNA of MCP-1, IL-6 and IL-8 that may induce a proinflammatory phenotype in endothelial cells. mRNA expression of …

Cancer ResearchPathologymedicine.medical_specialtyOsteolysisVascular Cell Adhesion Molecule-1Bone NeoplasmsOsteolysisBiologyurologic and male genital diseasesModels BiologicalProinflammatory cytokineOsteoclastmedicineHumansCarcinoma Renal CellCells CulturedCell adhesion moleculeMonocyteBone metastasisEndothelial Cellsmedicine.diseaseIntercellular Adhesion Molecule-1Kidney NeoplasmsEndothelial stem cellmedicine.anatomical_structureOncologyGene Expression RegulationCulture Media ConditionedCancer researchCytokinesCytokine secretionInflammation MediatorsE-SelectinInternational journal of oncology
researchProduct

Differential diagnosis of histogenetically distinct human epithelial renal tumours with a monoclonal antibody against gamma-glutamyltransferase.

1991

The localization of membrane-bound gamma-glutamyltransferase with monoclonal antibody (mAb) 138H11 proved to be of value for differential diagnosis of renal cancer, since it correlated with the histogenetic profile of human epithelial renal tumors. Immunoreactive gamma-glutamyltransferase was located in the proximal tubule in all normal human kidneys (15/15) examined thus far by both ultrastructural and immunohistochemical techniques. From 68 epithelial renal cancers tested 31/31 clear-cell carcinomas and 15/16 chromophilic carcinomas expressed the target epitope of mAb 138H11. In contrast, 0/11 oncytomas, 0/9 chromophobic carcinomas, and 0/1 Duct-Bellini carcinoma were immunoreactive. Thes…

Cancer ResearchPathologymedicine.medical_specialtymedicine.drug_classImmunologyHistogenesisBiologyurologic and male genital diseasesMonoclonal antibodyKidneyEpitopeEpitheliumDiagnosis DifferentialImmunoenzyme TechniquesFetusCarcinomamedicineImmunology and AllergyHumansMicroscopy ImmunoelectronKidneyCancerAntibodies Monoclonalgamma-GlutamyltransferaseClinical Enzyme Testsmedicine.diseaseKidney Neoplasmsmedicine.anatomical_structureOncologyImmunohistochemistryDifferential diagnosisCancer immunology, immunotherapy : CII
researchProduct

Novel chromosome copy number changes to predict clinical response to sunitinib in patients with advanced renal cell carcinoma

2015

4552 Background: Sunitinib is a 1st-line therapy for clear cell Renal Cell Carcinoma (ccRCC); however, 20-30% of tumors show primary resistant disease (PRD) with progression as the best response. T...

Cancer ResearchSunitinibbusiness.industryChromosomeDiseaseurologic and male genital diseasesmedicine.diseaseClear cell renal cell carcinomaOncologyRenal cell carcinomamedicineCancer researchIn patientbusinessmedicine.drug
researchProduct

Loss of tumor suppressor protein PTEN during renal carcinogenesis

2002

The tumor suppressor gene PTEN (phosphatase and tensin homologue deleted from chromosome 10) encodes a dual specific protein and phospholipid phosphatase that affects cell proliferation, apoptosis and migration. In our study, we examined protein expression of PTEN in renal carcinogenesis. PTEN protein levels were examined in 42 clear cell renal cell carcinomas (ccRCC) and oncocytomas as well as in the corresponding normal renal tissue of the same patients using Western blot analysis. Cellular localization was analyzed by immunohistochemistry. PTEN was highly expressed in all investigated normal renal tissue specimens. Immunohistochemical analysis showed an almost exclusive staining of proxi…

Cancer ResearchTumor suppressor genebiologyurologic and male genital diseasesmedicine.disease_causeBlotOncologymedicineCancer researchbiology.proteinTensinPTENCarcinogenesisImmunostainingClear cellCellular localizationInternational Journal of Cancer
researchProduct

Dual-Time Point [68Ga]Ga-PSMA-11 PET/CT Hybrid Imaging for Staging and Restaging of Prostate Cancer

2020

Routine [68Ga]Ga-PSMA-11 PET/CT (one hour post-injection) has been shown to accurately detect prostate cancer (PCa) lesions. The goal of this study is to evaluate the benefit of a dual-time point imaging modality for the staging and restaging of PCa patients. Biphasic [68Ga]Ga-PSMA-11 PET/CT of 233 patients, who underwent early and late scans (one/three hours post-injection), were retrospectively studied. Tumor uptake and biphasic lesion detection for 215 biochemically recurrent patients previously treated for localized PCa (prostatectomized patients (P-P)/irradiated patients (P-I) and 18 patients suspected of having primary PCa (P-T) were separately evaluated. Late [68Ga]Ga-PSMA-11 PET/CT …

Cancer Research[<sup>68</sup>Ga]Ga-PSMA PET/CTurologic and male genital diseaseslcsh:RC254-282030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicinedelayed imagingmedicineLymph nodebiphasic imagingPET-CTlesion positivity rateLesion detectionbusiness.industrymedicine.diseaseprostate cancerdual-time point imaginglcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.anatomical_structureOncology030220 oncology & carcinogenesisTracer uptakeCt imagingPreviously treatedbusinessNuclear medicineDual time pointCancers
researchProduct

Tracheal development and the von Hippel-Lindau tumor suppressor homolog in Drosophila.

2000

von Hippel-Lindau disease is a hereditary cancer syndrome. Mutations in the VHL tumor suppressor gene predispose individuals to highly vascularized tumors. However, VHL-deficient mice die in utero due to a lack of vascularization in the placenta. To resolve the contradiction, we cloned the Drosophila VHL homologue (d-VHL) and studied its function. It showed an overall 50% similarity to the human counterpart and 76% similarity in the crucial functional domain: the elongin C binding site. The putative d-VHL protein can bind Drosophila elongin C in vitro. During embryogenesis, d-VHL is expressed in the developing tracheal regions where tube outgrowth no longer occurs. Reduced d-VHL activity (u…

Cancer Researchendocrine system diseasesTumor suppressor geneUbiquitin-Protein LigasesMolecular Sequence Dataurologic and male genital diseasesTube fusionLigasesRNA interferenceVon Hippel–Lindau tumor suppressorGeneticsmedicineAnimalsHumansGenes Tumor SuppressorAmino Acid SequenceVon Hippel–Lindau diseaseCloning MolecularneoplasmsMolecular BiologyGeneticsbiologyTumor Suppressor ProteinsProteinsCell migrationEmbryomedicine.diseasePhenotypefemale genital diseases and pregnancy complicationsCell biologyTracheaPhenotypeVon Hippel-Lindau Tumor Suppressor Proteinbiology.proteinDrosophilaOncogene
researchProduct

Involvement of the chromosomal region 11q13 in renal oncocytoma: case report and literature review.

1997

Renal oncocytomas comprise a cytogenetically heterogeneous group of tumors consisting potentially of cytogenetic distinguishable subgroups. Review of the literature revealed loss of chromosome 1 and Y as a possible anomaly for at least one subset of oncocytomas. The frequent finding of rearrangements involving chromosome 11 band q13 characterizes another subset of oncocytomas. We report the cytogenetic and pathological features of a renal oncocytoma diagnosed in a 72-year-old woman and found a t(9;11)(p23;q13) as a consistent abnormality. This supports the idea that translocations involving 11q13 define a further subset of oncocytoma. (C) Elsevier Science Inc., 1997.

Cancer Researchmedicine.medical_specialtyPathologyChromosomes Human Pair 21Chromosomes Human Pair 20Chromosomal translocationChromosome DisordersBiologyurologic and male genital diseasesTranslocation GeneticGeneticsmedicineAdenoma OxyphilicHumansOncocytomaRenal oncocytomaCYTOGENETIC ABNORMALITIESMolecular BiologyAgedGeneticsChromosome AberrationsChromosomes Human Pair 11CytogeneticsChromosomeLOCALIZATIONKaryotypemedicine.diseaseTUMORSGENEKidney NeoplasmsChromosome BandingChromosomal regionFemaleAbnormalityChromosomes Human Pair 9Cancer genetics and cytogenetics
researchProduct

A proposed new model for prognostic stratification of poor-risk patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy.

2014

e15588 Background: The stratification of poor risk mRCC patients in the era of targeted therapy represents an unmet medical need. We analyzed, individually, each prognostic factor included in modif...

Cancer Researchmedicine.medical_specialtyPrognostic factorPoor riskbusiness.industrymedicine.medical_treatmenturologic and male genital diseasesmedicine.diseasePrognostic stratificationStratification (mathematics)Targeted therapyOncologyRenal cell carcinomaMedicinebusinessIntensive care medicine
researchProduct

Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal re…

2014

Background The incidence of acute kidney injury (AKI) is estimated at 10 to 20% in patients admitted to intensive care units (ICU) and often requires renal replacement therapy (RRT). ICU mortality in AKI patients can exceed 50%. Venous catheters are the preferred vascular access method for AKI patients requiring RRT, but carry a risk of catheter thrombosis or infection. Catheter lock solutions are commonly used to prevent such complications. Heparin and citrate locks are both widely used for tunneled, long-term catheters, but few studies have compared citrate versus heparin for patients with short-term, non-tunneled catheters. We aim to compare citrate 4% catheter lock solution versus hepar…

Catheter Obstructionmedicine.medical_specialtyCatheterization Central VenousTime Factorsmedicine.medical_treatmentHemodialysis CatheterCatheter ObstructionMedicine (miscellaneous)urologic and male genital diseasesHospitals UniversityStudy ProtocolAcute renal failureClinical ProtocolsDouble-Blind MethodRenal DialysisCitrate lockIntensive careUpper Extremity Deep Vein ThrombosisProhibitinsmedicineCentral Venous CathetersHumansPharmacology (medical)Heparin lockRenal replacement therapyCitratesProspective StudiesContraindicationbusiness.industryHeparinAcute kidney injuryAnticoagulantsEquipment DesignAcute Kidney Injurymedicine.diseasefemale genital diseases and pregnancy complicationsSurgeryCatheterIntensive Care UnitsTreatment OutcomeResearch DesignHemodialysisHemodialysisFranceCritically ill patientbusinessCatheter lockTrials
researchProduct